DE60333786D1 - Verfahren und immunmodulierende nukleinsäurezusammensetzungen zur vorbeugung und behandlungvon erkrankungen - Google Patents
Verfahren und immunmodulierende nukleinsäurezusammensetzungen zur vorbeugung und behandlungvon erkrankungenInfo
- Publication number
- DE60333786D1 DE60333786D1 DE60333786T DE60333786T DE60333786D1 DE 60333786 D1 DE60333786 D1 DE 60333786D1 DE 60333786 T DE60333786 T DE 60333786T DE 60333786 T DE60333786 T DE 60333786T DE 60333786 D1 DE60333786 D1 DE 60333786D1
- Authority
- DE
- Germany
- Prior art keywords
- preventing
- treating
- relates
- nucleic acid
- methods
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000002519 immonomodulatory effect Effects 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 3
- 102000039446 nucleic acids Human genes 0.000 title abstract 3
- 108020004707 nucleic acids Proteins 0.000 title abstract 3
- 150000007523 nucleic acids Chemical class 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 230000001363 autoimmune Effects 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000035790 physiological processes and functions Effects 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biotechnology (AREA)
- Rheumatology (AREA)
- Genetics & Genomics (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42864302P | 2002-11-21 | 2002-11-21 | |
PCT/US2003/037157 WO2004047734A2 (en) | 2002-11-21 | 2003-11-21 | Methods and immune modulatory nucleic acid compositions for preventing and treating disease |
Publications (1)
Publication Number | Publication Date |
---|---|
DE60333786D1 true DE60333786D1 (de) | 2010-09-23 |
Family
ID=32393438
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60333786T Expired - Lifetime DE60333786D1 (de) | 2002-11-21 | 2003-11-21 | Verfahren und immunmodulierende nukleinsäurezusammensetzungen zur vorbeugung und behandlungvon erkrankungen |
Country Status (15)
Country | Link |
---|---|
US (1) | US7811813B2 (de) |
EP (5) | EP2353614A1 (de) |
JP (2) | JP4750419B2 (de) |
CN (2) | CN101955976A (de) |
AT (1) | ATE477000T1 (de) |
AU (2) | AU2003294400B2 (de) |
CA (1) | CA2507249A1 (de) |
DE (1) | DE60333786D1 (de) |
DK (1) | DK1569696T3 (de) |
ES (1) | ES2350576T3 (de) |
IL (1) | IL168715A (de) |
NZ (1) | NZ540276A (de) |
PT (1) | PT1569696E (de) |
SI (1) | SI1569696T1 (de) |
WO (1) | WO2004047734A2 (de) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7935675B1 (en) | 1994-07-15 | 2011-05-03 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6225292B1 (en) * | 1997-06-06 | 2001-05-01 | The Regents Of The University Of California | Inhibitors of DNA immunostimulatory sequence activity |
EP1794174B1 (de) * | 2004-09-01 | 2012-06-06 | Dynavax Technologies Corporation | Methoden und zusammensetzungen zur hemmung von angeborener immunität und autoimmunität |
WO2006136821A1 (en) * | 2005-06-22 | 2006-12-28 | Astex Therapeutics Limited | Pharmaceutical compounds |
WO2007147007A2 (en) * | 2006-06-13 | 2007-12-21 | Bayhill Therapeutics, Inc. | Methods and immune modulatory nucleic acid compositions for preventing and treating disease |
US20100143372A1 (en) * | 2006-12-06 | 2010-06-10 | Medimmune, Llc | Interferon alpha-induced pharmacodynamic markers |
US20100261172A1 (en) * | 2007-05-03 | 2010-10-14 | Medimmune, Llc | Interferon alpha-induced pharmacodynamic markers |
CA2686861A1 (en) * | 2007-05-03 | 2008-11-13 | Medimmune, Llc | Interferon alpha-induced pharmacodynamic markers |
EP2361980B1 (de) | 2007-10-26 | 2016-12-07 | Dynavax Technologies Corporation | Verfahren und Zusammensetzungen zur Hemmung von Immunantworten und Autoimmunität |
PT2411521E (pt) | 2009-03-25 | 2015-04-21 | Univ Texas | Composições para estimulação de resistência imunitária inata de mamíferos contra patogénicos |
SG186380A1 (en) | 2010-06-16 | 2013-01-30 | Dynavax Tech Corp | Methods of treatment using tlr7 and/or tlr9 inhibitors |
SE535625C2 (sv) | 2010-10-28 | 2012-10-16 | Toleranzia Ab | Nya kompositioner och förfaranden för behandling av autoimmuna och allergiska sjukdomar |
US20130236453A1 (en) * | 2012-03-12 | 2013-09-12 | The Ohio State University | Methods and Compositions for Modulating Acute Graft-versus-Host Disease using miR-155 Specific Inhibitors |
WO2013160865A1 (en) | 2012-04-26 | 2013-10-31 | Toleranzia Ab | Immunotolerizing fusion proteins for treatment of multiple sclerosis |
US9868955B2 (en) | 2012-09-29 | 2018-01-16 | Dynavax Technologies Corporation | Human toll-like receptor inhibitors and methods of use thereof |
US9228184B2 (en) * | 2012-09-29 | 2016-01-05 | Dynavax Technologies Corporation | Human toll-like receptor inhibitors and methods of use thereof |
WO2016044839A2 (en) | 2014-09-19 | 2016-03-24 | The Board Of Regents Of The University Of Texas System | Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds |
RU2752608C2 (ru) | 2016-11-01 | 2021-07-29 | Ново Нордиск А/С | Толерогенная днк-вакцина |
US11279745B2 (en) | 2019-04-26 | 2022-03-22 | Novo Nordisk A/S | Tolerogenic DNA vaccine |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
US4425732A (en) | 1981-06-17 | 1984-01-17 | Kania Tadeusz E | Animal trap |
US4650675A (en) | 1983-08-18 | 1987-03-17 | The Children's Medical Center Corporation | Oligonucleotide conjugates |
US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
US5218103A (en) | 1988-05-26 | 1993-06-08 | University Patents, Inc. | Nucleoside thiophosphoramidites |
US5278302A (en) | 1988-05-26 | 1994-01-11 | University Patents, Inc. | Polynucleotide phosphorodithioates |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
AU8200191A (en) | 1990-07-09 | 1992-02-04 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | High efficiency packaging of mutant adeno-associated virus using amber suppressions |
US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
DE69233013T2 (de) | 1991-08-20 | 2004-03-04 | The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer | Adenovirus vermittelter gentransfer in den gastrointestinaltrakt |
CA2194761C (en) * | 1994-07-15 | 2006-12-19 | Arthur M. Krieg | Immunomodulatory oligonucleotides |
US6207646B1 (en) * | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US5712258A (en) | 1995-03-23 | 1998-01-27 | The Trustees Of The University Of Pennsylvania | Inotropic ADP and ATP analogues and their pharmaceutical compositions |
US5939400A (en) | 1996-02-26 | 1999-08-17 | The Board Of Trustees Of The Leland Stanford Junior University | DNA vaccination for induction of suppressive T cell response |
AU3225097A (en) | 1996-06-03 | 1998-01-05 | Auragen, Inc. | Immunotherapy for autoimmune disease |
DE69733020T2 (de) * | 1996-10-11 | 2006-02-16 | The Regents Of The University Of California, Oakland | Immunostimulierende oligonucleotidekonjugate |
US6406705B1 (en) * | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
WO1998052581A1 (en) | 1997-05-20 | 1998-11-26 | Ottawa Civic Hospital Loeb Research Institute | Vectors and methods for immunization or therapeutic protocols |
US6225292B1 (en) * | 1997-06-06 | 2001-05-01 | The Regents Of The University Of California | Inhibitors of DNA immunostimulatory sequence activity |
US6087341A (en) | 1998-02-12 | 2000-07-11 | The Board Of Trustees Of The Leland Standford Junior University | Introduction of nucleic acid into skin cells by topical application |
US7030098B2 (en) * | 1999-03-12 | 2006-04-18 | The Board Of Trustees Of The Leland Stanford Junior University | DNA vaccination for treatment of autoimmune disease |
US6949520B1 (en) * | 1999-09-27 | 2005-09-27 | Coley Pharmaceutical Group, Inc. | Methods related to immunostimulatory nucleic acid-induced interferon |
AU2001229472A1 (en) * | 2000-01-10 | 2001-07-24 | Elim Biopharmaceuticals, Inc. | Novel plasmid dna vectors |
ES2307568T3 (es) * | 2000-12-08 | 2008-12-01 | Coley Pharmaceutical Gmbh | Acidos nucleicos de tipo cpg y metodos de uso de los mismos. |
NZ533294A (en) | 2001-11-21 | 2007-06-29 | Univ Leland Stanford Junior | Polynucleotide therapy for diabetes associated with self-proteins, -polypeptides and -peptides |
US20050002953A1 (en) * | 2003-05-06 | 2005-01-06 | Jens Herold | SARS-coronavirus virus-like particles and methods of use |
CA2540890A1 (en) * | 2003-10-03 | 2005-04-14 | Bayhill Therapeutics, Inc. | Treatment of demyelinating autoimmune disease with modified ordered peptides |
WO2007147011A2 (en) * | 2006-06-13 | 2007-12-21 | Bayhill Therapeutics, Inc. | Polynucleotide therapy |
US8642040B2 (en) * | 2006-07-24 | 2014-02-04 | Biogen Idec Ma Inc. | Methods for promoting myelination, neuronal survival and oligodendrocyte differentiation via administration of Sp35 or TrkA antagonists |
WO2009099642A2 (en) * | 2008-02-05 | 2009-08-13 | The Board Of Trustees Of The Leland Stanford Junior University | Proteomic analysis of active multiple sclerosis lesions |
-
2003
- 2003-11-21 AU AU2003294400A patent/AU2003294400B2/en not_active Ceased
- 2003-11-21 WO PCT/US2003/037157 patent/WO2004047734A2/en active Application Filing
- 2003-11-21 EP EP10008311A patent/EP2353614A1/de not_active Withdrawn
- 2003-11-21 AT AT03789883T patent/ATE477000T1/de active
- 2003-11-21 SI SI200331894T patent/SI1569696T1/sl unknown
- 2003-11-21 US US10/524,643 patent/US7811813B2/en not_active Expired - Fee Related
- 2003-11-21 NZ NZ540276A patent/NZ540276A/en not_active IP Right Cessation
- 2003-11-21 EP EP10008310A patent/EP2329827A3/de not_active Withdrawn
- 2003-11-21 ES ES03789883T patent/ES2350576T3/es not_active Expired - Lifetime
- 2003-11-21 EP EP03789883A patent/EP1569696B1/de not_active Expired - Lifetime
- 2003-11-21 CN CN2009101704078A patent/CN101955976A/zh active Pending
- 2003-11-21 JP JP2004555515A patent/JP4750419B2/ja not_active Expired - Fee Related
- 2003-11-21 EP EP10008309A patent/EP2298360A3/de not_active Withdrawn
- 2003-11-21 CN CNB2003801077301A patent/CN100546657C/zh not_active Expired - Fee Related
- 2003-11-21 DK DK03789883.0T patent/DK1569696T3/da active
- 2003-11-21 CA CA002507249A patent/CA2507249A1/en not_active Abandoned
- 2003-11-21 DE DE60333786T patent/DE60333786D1/de not_active Expired - Lifetime
- 2003-11-21 EP EP10008312A patent/EP2322186A3/de not_active Withdrawn
- 2003-11-21 PT PT03789883T patent/PT1569696E/pt unknown
-
2005
- 2005-05-19 IL IL168715A patent/IL168715A/en active IP Right Revival
-
2009
- 2009-03-18 AU AU2009201102A patent/AU2009201102A1/en not_active Abandoned
-
2011
- 2011-02-15 JP JP2011029297A patent/JP2011148801A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
NZ540276A (en) | 2007-12-21 |
CA2507249A1 (en) | 2004-06-10 |
AU2003294400B2 (en) | 2008-12-18 |
AU2003294400A1 (en) | 2004-06-18 |
ATE477000T1 (de) | 2010-08-15 |
PT1569696E (pt) | 2010-11-11 |
US20050261215A1 (en) | 2005-11-24 |
DK1569696T3 (da) | 2010-11-15 |
ES2350576T3 (es) | 2011-01-25 |
EP2329827A2 (de) | 2011-06-08 |
EP1569696A2 (de) | 2005-09-07 |
EP2298360A2 (de) | 2011-03-23 |
JP2006514933A (ja) | 2006-05-18 |
WO2004047734A2 (en) | 2004-06-10 |
IL168715A (en) | 2011-09-27 |
CN101955976A (zh) | 2011-01-26 |
JP4750419B2 (ja) | 2011-08-17 |
SI1569696T1 (sl) | 2010-12-31 |
WO2004047734A3 (en) | 2004-08-12 |
CN1777447A (zh) | 2006-05-24 |
EP2353614A1 (de) | 2011-08-10 |
AU2009201102A1 (en) | 2009-04-09 |
EP1569696B1 (de) | 2010-08-11 |
EP2322186A3 (de) | 2011-07-13 |
JP2011148801A (ja) | 2011-08-04 |
CN100546657C (zh) | 2009-10-07 |
EP2329827A3 (de) | 2011-07-13 |
EP2322186A2 (de) | 2011-05-18 |
EP2298360A3 (de) | 2011-07-13 |
EP1569696A4 (de) | 2006-01-11 |
US7811813B2 (en) | 2010-10-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60333786D1 (de) | Verfahren und immunmodulierende nukleinsäurezusammensetzungen zur vorbeugung und behandlungvon erkrankungen | |
WO2003045316A3 (en) | Polynucleotide therapy | |
WO2003103586A3 (en) | METHOD OF TREATING AUTOIMMUNE OR INFLAMMATORY DISEASES USING COMBINATIONS OF INHIBITOR OLIGONUCLEOTIDES AND SMALL IMMUNOSTIMULATORY NUCLEIC ACID ANTAGONIST MOLECULES | |
WO2002006339A3 (en) | Proteins and nucleic acids encoding same | |
DE69935507D1 (de) | Verfahren und produkte zur stimulierung des immunsystems mittels immunotherapeutischer oligonukleotide und zytokine | |
WO2003030934A3 (en) | Cpg formulations and related methods | |
BRPI0407207A (pt) | Método para tratar, prevenir e diagnosticar uma infecção por heliocobacter | |
WO2005002526A3 (en) | Method and compositions for treatment of viral infections | |
WO2007147007A3 (en) | Methods and immune modulatory nucleic acid compositions for preventing and treating disease | |
IL169367A0 (en) | Defensin proteins | |
WO2006046017A3 (en) | Vaccine and nucleic acids capable of protecting poultry against colonisation by campylobacter | |
WO2003055912A3 (en) | Secreted proteins | |
ATE348161T1 (de) | Fctrx genannte proteine und dafür kodierende nuklein säure | |
IL169256A0 (en) | Metalloprotease proteins | |
DE60137459D1 (de) | Verfahren und zusammensetzungen zur behandlung oder prävention von bakteriellen infektionen | |
WO2002026826A3 (en) | Proteins and nucleic acids encoding same | |
WO2002070559A3 (en) | Nuclear hormone receptor ligand binding domains | |
WO2005030985A3 (en) | Use of amino acid sequences involved in the elongation of fatty acids in identifying and/or developing compounds for preventing and/or treating metabolic diseases | |
WO2005005471A3 (en) | Use of dg153 secreted protein products for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome | |
WO2001016158A3 (en) | Bridging integrator-2 (bin2) nucleic acid molecules and proteins and uses therefor | |
WO2003054178A3 (en) | Metalloprotease proteins | |
WO2004101618A3 (en) | Progestin-yol002c-cgi-45 receptor-related proteins | |
WO2004035626A3 (en) | Alpha macroglobulin protein family members | |
WO2004026905A3 (en) | Transporter/channel proteins | |
MXPA05012414A (es) | Proteina secretada similar a tnf. |